Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Faecal microbiota transplantation safe, effective for treating CDI in kids, young adults

20 Mar 2020

Faecal microbiota transplantation (FMT) may be performed in children and young adults to treat Clostridium difficile infection (CDI), with a study showing that the procedure is safe and effective and may be considered earlier in the disease course.

Researchers reviewed the medical records of 335 CDI patients aged 11 months to 23 years old, who were followed for at least 2 months following FMT. There were 120 patients with comorbid inflammatory bowel disease. Successful treatment was defined as the absence of recurrence throughout the follow-up.

A total of 271 patients (81 percent) achieved a successful outcome following FMT. Among the 64 patients who had CDI recurrence, 34 (53.1 percent) underwent repeat FMT, which was successful in 19 (55.9 percent). The overall success rate of one or two FMT procedures was 86.6 percent.

Factors associated with successful FMT included use of fresh donor stool (odds ratio [OR], 2.66, 95 percent confidence interval [CI], 1.39–5.08), delivery of FMT via colonoscopy (OR, 2.41, 95 percent CI, 1.26–4.61), nonrequirement of a feeding tube (OR, 2.08, 95 percent CI, 1.05–4.11), and having one lower total number of CDI episodes before FMT (OR, 1.20, 95 percent CI, 1.04–1.39).

Severe adverse events occurred in 17 patients (4.7 percent), including 10 hospitalizations. No deaths were recorded during the follow-up period.

The researchers called for additional investigation to determine the optimal timing and method of FMT for paediatric patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.